Zydus’ Usnoflast receives US FDA orphan drug designation to treat ...
20 hours ago · Zydus, a leading, discovery-based, global pharmaceutical company announced that the US FDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The US FDA's Office of Orphan Drug Products grants orphan status ...
Lilly's Omvoh receives US FDA approval to treat Crohn's disease in …
6 days ago · Lilly's Omvoh receives US FDA approval to treat Crohn's disease in adults: Indianapolis Friday, January 17, 2025, 12:00 Hrs [IST] Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults.
Frequency: Weekly (Goes into printing every Tuesday; On stands …
Launched on 21 December 2000, Chronicle Pharmabiz is the No. 1 Pharma news weekly in the South Asian markets; with a target readership that includes 100% coverage of top and middle management pharma professionals across the region.
Industry demands targeted reforms to drive pharma industry …
4 days ago · As India’s pharmaceutical and healthcare industries brace for the Union Budget 2025, key stakeholders highlight the need for targeted reforms to drive pharma industry growth, enhance global competitiveness, and improve healthcare access. Simplifying compliance via a single-window reporting ...
Six start-ups bestowed with new ‘heart of pharma’ at Pharmapack …
15 hours ago · Pharmapack Europe 2025 taking place from January 22 to 23, has selected six start-ups from its 26 strong field of innovators to receive the Pharmapack Europe ‘heart of pharma’. A special commendation given to these early-stage companies advancing new breakthrough technologies. To highlight the ...
AstraZeneca’s anti-complement medical therapy, eculizumab …
6 days ago · AstraZeneca Pharma India received a Central Drugs Standard Control Organisation (CDSCO) permission to import, sale or distribute ‘Eculizumab’ concentrate solution for infusion 300 mg (10mg/ml). Through this approval, eculizumab becomes a first anti-complement medical therapy indicated for ...
US FDA accepts and grants priority review status to Dizal’s ...
Jan 9, 2025 · Dizal, a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the US Food and Drug Administration (FDA) has accepted and granted priority review to the company’s New Drug Application (NDA) for sunvozertinib, an ...
News - Pharmabiz.com
Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic services,pharma tenders, pharma projects, pharma export & import, pharma laws & documents, pharma policies, pharma events, pharma company profiles, pharma studies, pharma marketing
India's most comprehensive portal on pharmaceutical News, …
Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic services,pharma tenders, pharma projects, pharma export & import, pharma laws & documents, pharma policies, pharma events, pharma company profiles, pharma studies, pharma marketing
Pfizer’s Hympavzi receives US FDA approval to treat adults and ...
Oct 14, 2024 · Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST]